STOCK TITAN

Jaguar Health, Inc. - JAGX STOCK NEWS

Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.

Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company specializing in the development of novel prescription medicines sustainably derived from natural plant sources in rainforest areas. The company's primary focus is on addressing gastrointestinal (GI) distress in both humans and animals, with an emphasis on chronic debilitating diarrhea and associated symptoms such as urgency, bowel incontinence, and cramping pain.

Jaguar Health operates through several subsidiaries, including Napo Pharmaceuticals, Inc., which develops and commercializes proprietary human GI pharmaceuticals globally. One of its flagship products, Mytesi® (crofelemer), is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company’s lead animal prescription drug candidate, Canalevia™, targets forms of diarrhea in dogs, while Equilevia™ supports total gut health in equine athletes.

In addition, Jaguar Health, through its Napo Pharmaceuticals subsidiary, is advancing the development of crofelemer with the ongoing OnTarget study, a pivotal Phase 3 clinical trial aimed at the preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Crofelemer has also been designated an Orphan Drug by the FDA and European Medicines Agency for short bowel syndrome (SBS) and microvillus inclusion disease (MVID).

Jaguar Health’s commitment to cancer supportive care is showcased through its preparation to launch Gelclair®, an FDA-approved oral mucositis prescription product, in Q3 2024. This initiative is part of their broader strategy to support cancer patients facing severe treatment side effects.

Beyond GI distress, Jaguar Health has a joint venture called Magdalena Biosciences, in collaboration with Filament Health Corp. This venture focuses on developing plant-based prescription medicines for mental health indications. A recent out-licensing agreement with Magdalena includes a botanical drug candidate for potential schizophrenia and psychoses indications.

Jaguar Health’s financial performance reflects consistent growth, with Q1 2024 revenue at approximately $2.4 million, showing a 20% increase from Q1 2023. Despite operational losses, the company continues to invest in research and development, particularly for rare disease treatments.

For more information, visit Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics, and Magdalena Biosciences. Stay connected with Jaguar Health on LinkedIn, X (formerly Twitter), and Instagram.

Rhea-AI Summary

Jaguar Health, Inc. (NASDAQ:JAGX) is set to file its Q3 2020 10-Q report on November 16, 2020. Management will host a conference call at 8:30 a.m. ET to discuss the financial results and provide business updates. Investors can join via dial-in numbers, with a replay option also available. The company is focused on developing plant-based pharmaceuticals to address GI distress, particularly chronic diarrhea. Notably, its product Mytesi® is FDA-approved for treating diarrhea in adults with HIV/AIDS.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.47%
Tags
conferences
-
Rhea-AI Summary

Jaguar Health, Inc. (NASDAQ:JAGX) announced that it received an extension from the Nasdaq Hearings Panel until December 23, 2020, to comply with the minimum bid price requirement for continued listing. The company must maintain a bid price of at least $1.00 per share for ten consecutive business days. Jaguar's recent efforts include expanded access programs for Mytesi and a $6 million royalty-based capital infusion. Additionally, Napo Pharmaceuticals initiated a pivotal Phase 3 trial for Mytesi in adult cancer patients experiencing diarrhea.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
none
-
Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) is hosting its inaugural "Diarrhea Dialogues" virtual event on October 20, 2020, from 3:00 PM to 4:30 PM ET, focused on supportive care for cancer patients experiencing diarrhea from cancer therapies. Key experts, including Jaguar's leadership and oncologists, will discuss the impact of diarrhea on cancer treatment and the importance of patient-physician dialogue. Jaguar's subsidiary, Napo Pharmaceuticals, has initiated a pivotal Phase 3 trial for crofelemer (Mytesi) in preventing cancer therapy-related diarrhea, currently approved for HIV/AIDS-related diarrhea relief.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.28%
Tags
none
Rhea-AI Summary

Jaguar Health, Inc. (NASDAQ:JAGX) granted nonstatutory stock options for 45,000 shares to a new employee effective October 13, 2020. The options, at an exercise price of $0.315 per share, are part of the Company's Inducement Award Plan and aim to incentivize new hires. The options vest 25% after nine months and monthly thereafter over the next 27 months, contingent on continued employment. Jaguar Health specializes in plant-based gastrointestinal products, with its MYTESI product approved by the U.S. FDA for treating noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
management
-
Rhea-AI Summary

Napo Pharmaceuticals, a subsidiary of Jaguar Health (NASDAQ:JAGX), unveiled the iAssist platform as part of its NapoCares patient support program. This web-based system automates the prescription process for Mytesi (crofelemer), an FDA-approved, plant-based treatment for diarrhea in HIV/AIDS patients. The platform enhances patient access by simplifying e-prescribing, prior authorizations, and eligibility checks, thereby promoting quicker treatment initiation. AssistRx developed iAssist, which also aids in tracking patient status and managing communications among healthcare providers, patients, and payers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
none
-
Rhea-AI Summary

Jaguar Health has appointed Melissa Yeager, J.D. as Senior Vice President of Regulatory Affairs & Quality Assurance. With extensive experience in the pharmaceutical industry, Yeager's leadership is expected to enhance the regulatory and quality functions at Jaguar and its subsidiary, Napo Pharmaceuticals. This move supports the ongoing commercialization of Mytesi and the pivotal Phase 3 clinical trial for diarrhea prophylaxis in adult cancer patients. Mytesi, a plant-based, FDA-approved antidiarrheal, assists patients with HIV/AIDS on antiretroviral therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.86%
Tags
management
Rhea-AI Summary

Jaguar Health, Inc. (NASDAQ:JAGX) has successfully closed the first $6 million tranche of a non-dilutive royalty financing transaction, potentially totaling $17 million, to support ongoing clinical trials for Mytesi (crofelemer). This financing will aid in developing treatments for cancer therapy-related diarrhea. Additionally, Jaguar has amended its agreement with Oasis Capital, allowing for $2,117,875.20 in accounts receivable purchases. The company aims to achieve financial sustainability in 2021 and has seen a 378% increase in Mytesi's Q2 2020 sales compared to Q1.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
none
-
Rhea-AI Summary

Jaguar Health, through its subsidiary Napo Pharmaceuticals, has launched a pivotal Phase 3 trial for crofelemer (Mytesi) aimed at preventing diarrhea in adult cancer patients undergoing targeted therapy. This 24-week, randomized, placebo-controlled study aims to address a significant unmet need as diarrhea affects over 650,000 chemotherapy patients in the U.S. annually. The trial is supported by an increased non-dilutive financing deal, now totaling $17 million, anticipated to expedite patient enrollment and site activation. Mytesi is FDA-approved for HIV/AIDS-related diarrhea, showcasing its therapeutic potential.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.35%
Tags
-
Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) announced that it has met the financial condition for an initial $5 million tranche of a potential $16 million non-dilutive royalty financing transaction. This financing is designed to support its development pipeline, particularly funding a pivotal clinical trial for Mytesi (crofelemer) aimed at treating cancer therapy-related diarrhea. The company has initiated an at-the-market program with Ladenburg Thalmann for future financing needs and anticipates the trial to start in Q4 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.81%
Tags
none
Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) announced a non-dilutive royalty financing agreement with a secured lender, securing $5 million for future royalties on Mytesi (crofelemer) sales. This funding will support regulatory activities, including a pivotal clinical trial for cancer therapy-related diarrhea (CTD), expected to commence in Q4 2020. The agreement may allow for additional financing up to $16 million by July 2021. CEO Lisa Conte emphasized that this option will not dilute shareholder equity and is based on the growing sales of Mytesi for HIV-related diarrhea.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.48%
Tags
none

FAQ

What is the current stock price of Jaguar Health (JAGX)?

The current stock price of Jaguar Health (JAGX) is $0.9255 as of December 20, 2024.

What is the market cap of Jaguar Health (JAGX)?

The market cap of Jaguar Health (JAGX) is approximately 10.7M.

What is Jaguar Health, Inc.?

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company developing novel, plant-based prescription medicines for gastrointestinal distress in humans and animals.

What are the main products of Jaguar Health?

Jaguar Health's main products include Mytesi® for noninfectious diarrhea in adults with HIV/AIDS, Canalevia™ for treating diarrhea in dogs, and Equilevia™ for equine gut health. They are also developing Gelclair® for oral mucositis.

What is Mytesi® used for?

Mytesi® (crofelemer) is an antidiarrheal medication approved by the FDA for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

What is the OnTarget study?

The OnTarget study is a Phase 3 clinical trial evaluating the effectiveness of crofelemer in preventing chemotherapy-induced overactive bowel (CIOB) in adults undergoing cancer therapy.

What recent achievements has Jaguar Health made?

Recent achievements include the approval of crofelemer as an Orphan Drug for SBS and MVID, initiation of phase 2 clinical trials in Europe, and preparation for the commercial launch of Gelclair®.

What is the focus of Magdalena Biosciences?

Magdalena Biosciences, a joint venture with Filament Health Corp., focuses on developing novel plant-based prescription medicines for mental health indications, including a botanical drug candidate for schizophrenia.

What are the financial highlights for Jaguar Health in Q1 2024?

In Q1 2024, Jaguar Health reported a combined net revenue of approximately $2.4 million, a 20% increase compared to Q1 2023. The company continues to invest in R&D, particularly for rare disease treatments.

What sustainability practices does Jaguar Health follow?

Jaguar Health employs sustainable harvesting practices under fair trade guidelines for the plant-based ingredients used in their products, ensuring high quality and ecological integrity.

How can I stay updated on Jaguar Health's developments?

You can stay updated by visiting Jaguar Health's official website, and following them on LinkedIn, X (formerly Twitter), and Instagram.

What is Gelclair® and its use?

Gelclair® is an FDA-approved prescription product used for managing and relieving pain associated with oral mucositis, a common side effect of cancer treatments.

Jaguar Health, Inc.

NASDAQ:JAGX

JAGX Rankings

JAGX Stock Data

10.70M
10.69M
12.02%
1.96%
3.6%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN FRANCISCO